For the 2018 Lancet paper on alcohol consumption in the Emerging Risk Factors Collaboration, UK Biobank and EPIC-CVD (Wood et al., 2018), the EPIC-CVD Consortium was supported by the following funding sources:

EPIC-CVD was supported by the European Commission Framework 7 (through the EPIC-CVD award; HEALTH-F2-2012-279233), and the European Research Council (through an Advanced Investigator Award to Professor John Danesh; 268834).

The EPIC-CVD Coordinating Centre has been underpinned by grants from the UK Medical Research Council (G0800270 and MR/L003120/1), British Heart Foundation (SP/09/002, RG/08/014 and RG13/13/30194), and National Institute for Health Research (through the National Institute for Health Research Cambridge Biomedical Research Centre).

EPIC-Asturias was supported by the Regional Government of Asturias.

EPIC-Greece was supported by the Hellenic Health Foundation.

EPIC-Oxford was supported by the UK Medical Research Council (MR/M012190/1) and Cancer Research UK (570/A16491).

EPIC-Ragusa was supported by the Sicilian Government, AIRE ONLUS Ragusa, and AVIS Ragusa.

EPIC-Sweden was supported by the Swedish Cancer Society, Swedish Scientific Council and Regional Government of Skåne and Västerbotten (Sweden).

EPIC-Turin was also supported by the Compagnia di San Paolo and the Human Genetics Foundation-Torino (HuGeF).